Cerity Partners
ALXN

Cerity Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Cerity Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-21,235
Closed -$3.32M – 760
2020
Q4 		$3.32M Buy
21,235
+746
+4% +$95.9K 0.11% 155
2020
Q3 		$2.35M Buy
20,489
+11,603
+131% +$1.25M 0.1% 149
2020
Q2 		$998K Buy
8,886
+10
+0.1% +$1.06K 0.06% 203
2020
Q1 		$797K Sell
8,876
-2,615
-23% -$257K 0.05% 237
2019
Q4 		$1.24M Sell
11,491
-4,093
-26% -$438K 0.06% 213
2019
Q3 		$1.53M Sell
15,584
-2,018
-11% -$227K 0.09% 197
2019
Q2 		$2.31M Sell
17,602
-1,939
-10% -$250K 0.15% 141
2019
Q1 		$2.64M Sell
19,541
-87
-0.4% -$10.8K 0.18% 132
2018
Q4 		$1.91M Sell
19,628
-692
-3% -$81.8K 0.13% 161
2018
Q3 		$2.83M Buy
20,320
+554
+3% +$69.5K 0.2% 130
2018
Q2 		$2.45M Sell
19,766
-1,644
-8% -$192K 0.18% 133
2018
Q1 		$2.39M Sell
21,410
-2,563
-11% -$306K 0.18% 134
2017
Q4 		$2.87M Sell
23,973
-2,791
-10% -$340K 0.19% 119
2017
Q3 		$3.75M Buy
26,764
+20,084
+301% +$2.73M 0.27% 92
2017
Q2 		$656K Buy
6,680
+4,861
+267% +$566K 0.05% 206
2017
Q1 		$221K Buy
+1,819
New +$235K 0.02% 402

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cerity Partners's ALXN Position: Q1 2021 in Review

Cerity Partners sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 21,235 shares — an estimated $3.32M sold.

Cerity Partners first reported a position in ALXN in Q1 2017 and held it in 16 quarters. The position peaked at $3.75M in Q3 2017. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Cerity Partners reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Cerity Partners sold 21,235 Alexion Pharmaceuticals shares in Q1 2021, an estimated $3.32M.
  • Cerity Partners first reported a position in Alexion Pharmaceuticals in Q1 2017 and held it in 16 quarters.
  • Cerity Partners's Alexion Pharmaceuticals position peaked at $3.75M in Q3 2017.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Cerity Partners's 13F filing for Q1 2021, filed 12 May 2021.